Zhejiang University Cancer Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jiang, Shusuan
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
240
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
11/26
12/27
NCT06378242: To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Recruiting
1/2
24
RoW
Disitamab Vedotin for injection, RC48
RemeGen Co., Ltd.
High-risk Non-muscle Invasive Bladder Cancer
03/29
12/29
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT06689163: A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

Recruiting
1/2
66
RoW
HRS-1167 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets
Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
11/25
12/26
NCT06186414: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Recruiting
1
152
RoW
SIM0237, SIM0237 and BCG
Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai Xianxiang Medical Technology Co., Ltd.
Non-Muscle-Invasive Bladder Cancer (NMIBC)
01/27
12/30
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting
1
153
RoW
HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
12/24
12/24
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Recruiting
1
169
US, RoW
ABSK121-NX
Abbisko Therapeutics Co, Ltd
Solid Tumor
03/25
06/25
NCT05843305: A Study of BPI-452080 in Subjects With Solid Tumors

Not yet recruiting
1
87
RoW
BPI-452080
Betta Pharmaceuticals Co., Ltd.
Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease
03/25
10/25

Download Options